Despite universal coverage including screening, Thailand’s incidence rate is nearly three times higher than that of the United States, suggesting a different approach is needed to reduce the burden of cervical cancer statistics doing. Q-Pad offers a diagnostic test that replaces the Pap smear and provides an accessible, non-invasive method to screen for HR-HPV. This is a new menstrual pad that is used twice during menstruation and helps remove an additional barrier from the traditional Pap test which can be barbaric, not easily accessible, time consuming and costly. increase. Each Q-Pad contains a removable cotton strip that is sent to the lab for clinical testing. User receives lab report results on the Qvin app, healthcare provider, or properly trained outreach her worker.
“As part of our efforts to help Thai women prevent cervical cancer, we believe Qvin’s Q-Pad is one of the most innovative ways to early screen for HR-HPV. We believe this is a progressive and modern approach to cervical cancer, said Dr. Chairat Panthuraamphorn, Managing Director and CEO of Samitivej Hospital.
“Receiving FDA approval in Thailand is exciting and contributes to our vision of a world in which no women die from cancers like cervical cancer, which are completely preventable if detected early.” , Kubin. “The approval not only marks a milestone in our journey to advance research in women, but also provides an accessible test for millions of people in Thailand to identify HR-HPV early. And that means we can eliminate cervical cancer there and look for more countries … to follow.”
“It is well known that regular HPV screening saves lives by leading to the detection of cervical precancer, which leads to cervical cancer, the leading killer of women worldwide. Before, patients and healthcare professionals can be treated effectively,” said Dr. Paul D. Blumenthal, professor emeritus of obstetrics and gynecology at Stanford University. “We are thrilled to have his Q-Pad approved in Thailand, which has a high incidence of cervical cancer. Access to the test means users can manage their health easily and efficiently. increase.”
FDA Thailand regulatory approval was achieved in collaboration with Qvin, N Health Laboratories and Bangkok Health Research Center (BHRC). In addition to regulatory approval, the Bangkok Health Research Center plans to conduct her 1,500-person comparative study on HR-HPV using both Q-Pad and PAP smears. The data collected will be used to further understand her HPV and cervical cancer prevalence in Thailand and to formulate official strategies to screen for HR-HPV earlier and save lives.
